| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1103686011 |
| P356 | DOI | 10.1038/S41591-018-0010-1 |
| P932 | PMC publication ID | 6117613 |
| P698 | PubMed publication ID | 29713085 |
| P50 | author | Carl H. June | Q19277113 |
| Simon F Lacey | Q56978267 | ||
| Joseph A. Fraietta | Q85544113 | ||
| Irina Kulikovskaya | Q85544118 | ||
| Minnal Gupta | Q85544121 | ||
| Bruce L. Levine | Q85544154 | ||
| F Brad Johnson | Q87970833 | ||
| E. John Wherry | Q88954779 | ||
| Jan Melenhorst | Q90374440 | ||
| Jun Xu | Q96211892 | ||
| David L. Porter | Q110797660 | ||
| Noelle V. Frey | Q110799186 | ||
| Edward Pequignot | Q117233462 | ||
| P2093 | author name string | Yan Wang | |
| Fang Chen | |||
| Li Liu | |||
| Jennifer L Brogdon | |||
| Hans Bitter | |||
| Sadik H Kassim | |||
| Alexander C Huang | |||
| Wei-Ting Hwang | |||
| Lifeng Tian | |||
| Regina M Young | |||
| Changfeng Zhang | |||
| Felipe Bedoya | |||
| Iulian Pruteanu-Malinici | |||
| Alina C Boesteanu | |||
| Corin Dorfmeier | |||
| David E Ambrose | |||
| Donald L Siegel | |||
| Elena J Orlando | |||
| Harit Parakandi | |||
| Megan M Davis | |||
| Mercy Gohil | |||
| Nicholas Wilcox | |||
| Roddy S O'Connor | |||
| Stefan Lundh | |||
| P2860 | cites work | Telomere measurement by quantitative PCR | Q24529938 |
| Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy | Q24596055 | ||
| Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients | Q24598792 | ||
| T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Q24632975 | ||
| Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks | Q24633890 | ||
| Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials | Q27312288 | ||
| Specific Association of Human Telomerase Activity with Immortal Cells and Cancer | Q27860801 | ||
| edgeR: a Bioconductor package for differential expression analysis of digital gene expression data | Q27860819 | ||
| A human memory T cell subset with stem cell-like properties | Q28248395 | ||
| Restoring function in exhausted CD8 T cells during chronic viral infection | Q28289222 | ||
| An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells | Q28547142 | ||
| HTSeq--a Python framework to work with high-throughput sequencing data | Q29614489 | ||
| STAR: ultrafast universal RNA-seq aligner | Q29615052 | ||
| Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
| Natural innate and adaptive immunity to cancer | Q29620313 | ||
| Early immunologic correlates of HIV protection can be identified from computational analysis of complex multivariate T-cell flow cytometry assays. | Q30512377 | ||
| Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. | Q30985619 | ||
| Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells | Q33831940 | ||
| Automated identification of stratifying signatures in cellular subpopulations | Q33854094 | ||
| Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia | Q34009003 | ||
| Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation | Q34028816 | ||
| Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor | Q34041792 | ||
| Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired | Q34080914 | ||
| Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients | Q34161579 | ||
| Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells | Q34480237 | ||
| LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems | Q34700552 | ||
| Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells | Q34856800 | ||
| Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. | Q34859794 | ||
| Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. | Q34891171 | ||
| A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory | Q35586049 | ||
| Gene deregulation and chronic activation in natural killer cells deficient in the transcription factor ETS1 | Q36074924 | ||
| T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. | Q36215165 | ||
| Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses | Q36229406 | ||
| Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia | Q36651344 | ||
| CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients | Q36951727 | ||
| Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection | Q36979967 | ||
| Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. | Q37389018 | ||
| CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo. | Q37655544 | ||
| The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. | Q40050634 | ||
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial | Q40186710 | ||
| Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells | Q41259289 | ||
| Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia | Q41429394 | ||
| Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib | Q41601558 | ||
| Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. | Q42283389 | ||
| Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 | ||
| Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential | Q43452219 | ||
| Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions | Q44443175 | ||
| Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation | Q44451886 | ||
| Cues-pause-point training and simultaneous communication to teach the use of signed labeling repertoires. | Q50536441 | ||
| Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection. | Q51959814 | ||
| Molecular signature of CD8+ T cell exhaustion during chronic viral infection. | Q51970485 | ||
| Regulated expression of gp130 and IL-6 receptor alpha chain in T cell maturation and activation. | Q52184931 | ||
| Human CD4+ memory T cells are preferential targets for bystander activation and apoptosis. | Q54495387 | ||
| Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers | Q58211840 | ||
| The current status of liver transplantation | Q68246741 | ||
| Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol | Q80093221 | ||
| Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells | Q88853226 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 563-571 | |
| P577 | publication date | 2018-04-30 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. | |
| P478 | volume | 24 |
| Q92407428 | 'Off-the-shelf' allogeneic CAR T cells: development and challenges |
| Q99209887 | 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL |
| Q97866965 | 90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma |
| Q90413936 | A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy |
| Q64120024 | A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy |
| Q100750316 | Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy |
| Q92611061 | Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds |
| Q104503891 | Addressing patient to patient variability for autologous CAR T therapies |
| Q99628544 | Advances in CAR T-Cell Therapy for Aggressive B-NHL |
| Q92703407 | Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment |
| Q57053387 | Allogeneic CAR-T Cells: More than Ease of Access? |
| Q92405209 | An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment |
| Q91526765 | Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? |
| Q58883571 | Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity |
| Q90028964 | Are CAR T cells better than antibody or HCT therapy in B-ALL? |
| Q92864734 | At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids |
| Q92522868 | B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma |
| Q104610983 | Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses |
| Q95274320 | Biomarkers in individualized management of chimeric antigen receptor T cell therapy |
| Q91736550 | Brain immunology and immunotherapy in brain tumours |
| Q52385841 | Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic. |
| Q90677062 | CAR T Cell Therapy Progress and Challenges for Solid Tumors |
| Q99730742 | CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? |
| Q60047537 | CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success |
| Q64235860 | CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment |
| Q64891859 | CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. |
| Q90080719 | CAR T and CAR NK cells in multiple myeloma: Expanding the targets |
| Q90990072 | CAR T cell therapy: inroads to response and resistance |
| Q92245332 | CAR T cells for brain tumors: Lessons learned and road ahead |
| Q97524803 | CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences |
| Q98771206 | CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions |
| Q96306695 | CAR T-cell immunotherapy of B-cell malignancy: the story so far |
| Q90705235 | CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV |
| Q58572502 | CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge |
| Q64250623 | CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy |
| Q92296446 | CD19 CAR T cell product and disease attributes predict leukemia remission durability |
| Q92039571 | CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration |
| Q90482319 | CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy |
| Q90596725 | Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency |
| Q100455153 | Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas |
| Q92301970 | Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies |
| Q89895682 | Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data |
| Q59793960 | Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance |
| Q94526312 | Chimeric antigen receptor T cell therapy comes to clinical practice |
| Q90349845 | Chimeric antigen receptor T-cell therapies: Optimising the dose |
| Q100940706 | Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020? |
| Q97424540 | Chimeric antigen receptor signaling: Functional consequences and design implications |
| Q59329883 | Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia |
| Q93039099 | Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL |
| Q99247595 | Circulation of gut-preactivated naïve CD8+ T cells enhances antitumor immunity in B cell-defective mice |
| Q101139022 | Clinical CAR-T cell and Oncolytic Virotherapy for Cancer Treatment |
| Q90003885 | Clinical lessons learned from the first leg of the CAR T cell journey |
| Q92563650 | Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy |
| Q64248097 | Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma |
| Q45870279 | Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy |
| Q64118505 | Current State of Immunotherapy for Treatment of Glioblastoma |
| Q95648221 | Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response |
| Q58700983 | Cytokine release syndrome: grading, modeling, and new therapy |
| Q92034572 | Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells |
| Q99711501 | Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells |
| Q94503547 | Development of CAR-T cell therapy for B-ALL using a point-of-care approach |
| Q96155790 | Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells |
| Q90007167 | Dissecting the tumor-immune landscape in chimeric antigen receptor T-cell therapy: key challenges and opportunities for a systems immunology approach |
| Q98171149 | Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer |
| Q90334543 | Emerging Cellular Therapies for Cancer |
| Q90686044 | Emerging strategies for combination checkpoint modulators in cancer immunotherapy |
| Q93103183 | Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia |
| Q90380859 | Engineering Cell Surfaces by Covalent Grafting of Synthetic Polymers to Metabolically-Labeled Glycans |
| Q60924201 | Engineering and Design of Chimeric Antigen Receptors |
| Q91847813 | Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors |
| Q92059900 | Engineering strategies to overcome the current roadblocks in CAR T cell therapy |
| Q98292032 | Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design |
| Q92337122 | Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors |
| Q89457536 | Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma |
| Q92983054 | Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia |
| Q92836860 | Evolution of Next Generation Therapeutics: Past, Present, and Future of Precision Medicines |
| Q90761903 | GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab |
| Q92283987 | Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges |
| Q90862859 | Genetically engineered T cells for cancer immunotherapy |
| Q91899225 | Gut microbiome and CAR-T therapy |
| Q98181408 | IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors |
| Q92640152 | IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model |
| Q101476400 | IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells |
| Q97597166 | ISSUE HIGHLIGHTS - July 2020 |
| Q64278782 | Immune cells track hard-to-target brain tumours |
| Q64950921 | Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. |
| Q89626900 | Immunotherapy of lymphomas |
| Q90156172 | Immunotherapy of multiple myeloma |
| Q89453284 | Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction |
| Q97530682 | Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen |
| Q93093467 | Improving CAR T cell immunotherapy-mediated remissions for pediatric leukemia |
| Q92438272 | In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function |
| Q91919098 | Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity |
| Q89519257 | Interleukin-23 engineering improves CAR T cell function in solid tumors |
| Q64093637 | Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells |
| Q56886922 | Lack of Sprouty 1 and 2 enhances survival of effector CD8 T cells and yields more protective memory cells |
| Q92480675 | Large-scale expansion and characterization of CD3+ T-cells in the Quantum® Cell Expansion System |
| Q60922704 | Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia |
| Q64998779 | Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. |
| Q91240562 | L’émergence des traitements par cellules CAR-T dans les lymphomes |
| Q91742709 | Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy |
| Q92639482 | Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data |
| Q92150199 | Mechanisms of resistance to CAR T cell therapy |
| Q96231527 | Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies |
| Q92023481 | Metabolic interventions in the immune response to cancer |
| Q98720546 | Monitoring CAR T-cells using flow cytometry |
| Q96646541 | Monitoring CAR-T cell kinetics in clinical trials by multiparameteric flow cytometry: Benefits and challenges |
| Q100513877 | Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma |
| Q64102615 | Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies |
| Q64268744 | Multiparametric analysis of CD8 T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy |
| Q58548495 | Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies |
| Q94467230 | New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry |
| Q97420808 | Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients |
| Q91826113 | Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours |
| Q60947916 | Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report |
| Q88671244 | Only the best CAR T cells |
| Q92374995 | Optimization and Stability of Cell-Polymer Hybrids Obtained by "Clicking" Synthetic Polymers to Metabolically Labeled Cell Surface Glycans |
| Q91964127 | Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy |
| Q90690181 | Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia |
| Q92526117 | Peripheral Blood T-Cell Fitness Is Diminished in Patients With Pancreatic Carcinoma but Can Be Improved With Homeostatic Cytokines |
| Q90576088 | Precursor exhausted T cells: key to successful immunotherapy? |
| Q92480496 | Prevention of CAR-T-cell dysfunction |
| Q90453826 | Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor |
| Q100762007 | Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells |
| Q90220049 | Re-defining T-Cell Exhaustion: Subset, Function, and Regulation |
| Q90355383 | Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management |
| Q94503527 | Receptor signaling, transcriptional, and metabolic regulation of T cell exhaustion |
| Q89157989 | STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity |
| Q64983614 | Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. |
| Q91642886 | Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization |
| Q92880596 | Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies |
| Q95832157 | Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells |
| Q90855852 | Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic |
| Q93104450 | Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy |
| Q92959947 | Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation |
| Q92348600 | State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 |
| Q92404807 | Striking a Balance-Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation |
| Q58726929 | Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes |
| Q92405303 | T Cell Dysfunction in Cancer Immunity and Immunotherapy |
| Q92245345 | T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance |
| Q90423229 | T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma |
| Q93061113 | TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors |
| Q99418746 | Targeting the epigenetic regulation of antitumour immunity |
| Q58561607 | Teaching an old dog new tricks: next-generation CAR T cells |
| Q98292030 | The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing |
| Q64075706 | The Discovery of Biomarkers in Cancer Immunotherapy |
| Q64118716 | The Emergence of Universal Immune Receptor T Cell Therapy for Cancer |
| Q92354027 | The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells |
| Q57492021 | The Potential of CAR T Cell Therapy in Pancreatic Cancer |
| Q89515386 | The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 |
| Q90147870 | Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia |
| Q97568608 | Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma |
| Q92538413 | Understanding and Modulating Immunity With Cell Reprogramming |
| Q91871527 | Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies |
| Q102369590 | Using single-cell analysis to predict CAR T cell outcomes |
| Q90262300 | [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer] |
| Q91698361 | c-Jun overexpression in CAR T cells induces exhaustion resistance |
| Q96229980 | convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting |
Search more.